Qualitative differential screening

Details Qualitative differential screening Qualitative differential screening

2005-04-19

2005-04-19

Siew, Jeffrey (Department: 1637)

Chemistry: molecular biology and microbiology

Apparatus

Including measuring or testing

C435S006120, C435S007100, C435S091100, C435S091200, C536S022100, C536S023100, C536S024300, C536S024310, C536S024320, C536S024330

Reexamination Certificate

active

06881571

ABSTRACT:
The invention concerns a method for identifying and/or cloning nucleic acid regions representing qualitative differences associated with alternative splicing events and/or with insertions, deletions located in RNA transcribed genome regions, between two physiological situations, comprising either hybridization of RNA derived from the test situation with cDNA's derived from the reference situation and/or reciprocally, or double-strand hybridization of cDNA derived from the test situation with cDNA's derived from the reference situation; and identifying and/or cloning nucleic acids representing qualitative differences. The invention also concerns compositions or banks of nucleic acids representing qualitative differences between two physiological situations, obtainable by the above method, and their use as probe, for identifying genes or molecules of interest, or still for example in methods of pharmacogenomics, and profiling of molecules relative to their therapeutic and/or toxic effects. The invention further concerns the use of dysregulation of splicing RNA as markers for predicting molecule toxicity and/or efficacy, and as markers in pharmacogenomics.

REFERENCES:
patent: 5445934 (1995-08-01), Fodor et al.
patent: 5484702 (1996-01-01), Ludwig
patent: 5521297 (1996-05-01), Daggett et al.
patent: 5643729 (1997-07-01), Taniguchi et al.
patent: 5679541 (1997-10-01), Bonini et al.
patent: 5837832 (1998-11-01), Chee et al.
patent: 5908920 (1999-06-01), Sidransky
patent: 5922535 (1999-07-01), Huo et al.
patent: 6107088 (2000-08-01), Korneluk et al.
patent: 6251590 (2001-06-01), Schweighoffer et al.
patent: 6268170 (2001-07-01), Siddique et al.
patent: 0 806 478 (1997-11-01), None
patent: 2 664 287 (1992-01-01), None
patent: WO 94 12631 (1994-06-01), None
patent: WO 95 27052 (1995-10-01), None
patent: WO 96 26272 (1996-08-01), None
patent: WO 96 30512 (1996-10-01), None
patent: WO 97 04092 (1997-02-01), None
patent: WO 9727317 (1997-07-01), None
patent: WO 9729212 (1997-08-01), None
patent: WO 97 46679 (1997-12-01), None
patent: WO 98 02576 (1998-01-01), None
Alphey, L., “PCR-based method for isolation of full-length clones and splice variants from cDNA libraries”Biotechniques22:481-486 (1997).
Ambartsumian, N. et al., “Characterization of two splice variants of metastasis-associated human mts1 gene,” Gene 159(1): 125-130 (1995).
Ardley, et al., “Rapid isolation of genomic clones for individual members of human multigene families: Identification and localisation of UBE2L4, a novel member of a ubiquitin conjugating enzyme dispersed gene family”Cytogenetics and Cell Genetics, 79:188-192 (1997).
Bloom, T. J. and Beavo, J. A., “Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants,”Proc. Natl. Acad. Sci. USA93(24): 14188-14192 (1996).
Bonass, et al., “The rat amelogenin gene—some aspects of evolution and expression”Advances in Dental Research, 10:182-186 (1996).
Canton, H. et al., “Identification, Molecular Cloning, and Distribution of a Short Variant of the 5-Hydroxytryptamine2CReceptor Produced by Alternative Splicing,”Mol. Pharmacol.50(4): 799-807 (1996).
Cheng, J. et al., “Protection from Fas-Mediated Apoptosis by a Soluble Form of the Fas Molecule,”Science263(5154): 1759-1762 (1994).
Cooper, et al., “Gene therapy advances: utilization of alternative splicing as a control element in the chimeric-enzyme/prodrug therapy (cept) approach to primary and metastatic tumors”Journal of Clinical Ligand Assay., 19:80-84 (1996).
Drmanac et al., “Gene-Representing cDNA Clusters Defined by Hybridization of 57,419 Clones from Infant Brain Libraries with Short Oligonucleotide Probes,”Genomics37:29-40 (1996).
Ion, A. et al., “A novel Mutation in the Putative DNA Helicase XH2 is Responsible for Male-to-Female Sex Reversal Associated with an Atypical Form of the ATR-X Syndrome,”Am. J. Hum. Genet.58(6): 1185-1191 (1996).
Lisitsyn et al., “Comparative genomic analysis of tumors: Detection of DNA losses and amplification,”Proc. Natl. Acad. Sci. USA92:151-155 (1995).
Miller, R. D. and Riblet, R., “Improved phenol emulsion DNA reassociation technique (PERT) using thermal cycling”Nucleic Acids Research, 23:2339-2340 (1995).
Nakajima, T. et al., “A New Alternative Splice Variant of the Mouse FAS Antigen with a Deletion in the N-Terminal Portion of the Extracellular Domain,”Life Sci.58(9): 761-768 (1996).
Prashar et al., Analysis of differential gene expression by display of 3′ end restriction fragments of cDNAs,Proc. Natl. Acad. Sci. USA93:659-663 (1996).
Roemer, K. and Mueller-Lantzsch, N., “p53 transactivation domain mutant Q22, S23 is impaired for repression of promoters and mediation of apoptosis,”Oncogene12: 2069-2079 (1996).
Roth, J. A. et al., “Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer,”Nat. Med.2: 985-991 (1996).
Sabbatini, P. et al., “Essential role for p53-mediated transcription in E1A-induced apoptosis,”Genes Dev.9: 2184-2192 (1995).
Varesco, L. et al., “Mutation in a splice-donor site of the APC gene in a family with polyposis and late age of colonic cancer death,”Hum. Genet.93(3): 281-286 (1994).
Watanabe, K. et al., J. “Splicing Isoforms of Rat Ash/Grb2,”Biol. Chem.270(23): 13733-13739 (1995).
Zhao et al., “High-density cDNA filter analysis: a novel approach for large-scale, quantitative analysis of gene expression,”Gene, 156:207-213 (1995).
Zhu, Q. et al., “Deletion within the Src Homology Doman 3 of Bruton's Tyrosine Kinase Resulting in X-linked Agammaglobulinemia (XLA),”J. Exp. Med.180(2): 461-470 (1994).

Affiliated with

Also associated with

Rating

Qualitative differential screening does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Qualitative differential screening, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Qualitative differential screening will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3375809